Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,netReceivables,longTermDebt,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,otherCashflowsFromInvestingActivities,otherCashflowsFromFinancingActivities,changeToNetincome,netBorrowings,changeToOperatingActivities,depreciation,changeToAccountReceivables,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketChangePercent,regularMarketDayRange,ask,bid,regularMarketPreviousClose,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,currency,marketState,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,market,priceHint,exchangeDataDelayedBy,twoHundredDayAverageChangePercent,shortName,exchange,epsCurrentYear,priceEpsCurrentYear,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,country,website,maxAge,address1,industry,address2
t0,IMCR,245797000.0,43786100,19885000,,-33719000,,-29038000,20184000,8270000,-31881000,-31881000,82000,-1860000,,,,-4681000,8270000,40151000,0,-1838000,,-29038000,-29038000,211286000.0,135350000.0,245797000.0,25824000.0,381147000.0,88000.0,-378907000.0,19385000.0,413330000.0,2753000.0,313083000.0,54493000.0,2213000.0,546000.0,413330000.0,35063000.0,339519000.0,3812000.0,26436000.0,36437000.0,26359000.0,0.0,25000.0,209373000.0,287000000.0,183367000.0,-52000.0,-25979000.0,25000.0,-77627000.0,3059000.0,,,,,,285026000.0,en-US,US,EQUITY,True,Delayed Quote,0.5497645,34.425 - 35.38,0.0,0.0,34.56,30,29,finmb_133103539,NasdaqGS,Immunocore Holdings plc,GBP,70060,133485,6.9799995,0.25135034,27.77 - 61.99,-27.240002,-0.43942574,27.77,61.99,1620802800,1620802800,1620802800,USD,PRE,34.75,1630526402,0.18999863,34.94,35.38,34.425,17471,us_market,2,0,-0.08919105,Immunocore Holdings plc,NMS,-4.73,-7.346723,32.258858,2.4911423,0.07722351,38.152897,-3.402897,1521566976,15,America/New_York,EDT,-14400000,False,False,,,,61.99,27.77,32.26,38.15,70.06k,133.49k,43.79M,,21.57M,0.00%,34.77%,186.17k,4.21,,0.43%,159.33k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-280.43%,-323.25%,-22.77%,-64.85%,30.13M,1.01,0.20%,30.11M,-90.97M,-84.49M,,,313.08M,8.14,63.78M,25.95,6.23,,-56.03M,-27.12M,Value,OX14 4RY,Healthcare,291,"Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung, gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising breast, endometrial, ovarian, and small cell lung cancers; and GSK01 that is in a Phase I clinical trial. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.",Abingdon,44 1235 438600,United Kingdom,http://www.immunocore.com,86400,92 Park Drive,Biotechnology,Milton Park
t-1,IMCR,55346000.0,43786100,16043000,,-21027000,,-18880000,14171000,7420000,-21596000,-21596000,-1198000,-1103000,,,,-2147000,7420000,29016000,0,569000,,-18880000,-18880000,386230000.0,141848000.0,55346000.0,27227000.0,197194000.0,1000.0,-349869000.0,25006000.0,18984000.0,7219000.0,129716000.0,54998000.0,2230000.0,,18984000.0,36847000.0,152931000.0,197000.0,16708000.0,36654000.0,5783000.0,2450000.0,1813000.0,91963000.0,55958000.0,73029000.0,-171000.0,-20576000.0,1537000.0,-409000.0,-723000.0,36414000.0,-5827000.0,2324000.0,80000.0,-347000.0,97933000.0,en-US,US,EQUITY,True,Delayed Quote,0.5497645,34.425 - 35.38,0.0,0.0,34.56,30,29,finmb_133103539,NasdaqGS,Immunocore Holdings plc,GBP,70060,133485,6.9799995,0.25135034,27.77 - 61.99,-27.240002,-0.43942574,27.77,61.99,1620802800,1620802800,1620802800,USD,PRE,34.75,1630526402,0.18999863,34.94,35.38,34.425,17471,us_market,2,0,-0.08919105,Immunocore Holdings plc,NMS,-4.73,-7.346723,32.258858,2.4911423,0.07722351,38.152897,-3.402897,1521566976,15,America/New_York,EDT,-14400000,False,False,,,,61.99,27.77,32.26,38.15,70.06k,133.49k,43.79M,,21.57M,0.00%,34.77%,186.17k,4.21,,0.43%,159.33k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-280.43%,-323.25%,-22.77%,-64.85%,30.13M,1.01,0.20%,30.11M,-90.97M,-84.49M,,,313.08M,8.14,63.78M,25.95,6.23,,-56.03M,-27.12M,Value,OX14 4RY,Healthcare,291,"Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung, gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising breast, endometrial, ovarian, and small cell lung cancers; and GSK01 that is in a Phase I clinical trial. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.",Abingdon,44 1235 438600,United Kingdom,http://www.immunocore.com,86400,92 Park Drive,Biotechnology,Milton Park
t-2,IMCR,15548000.0,43786100,21609000,,-23622000,,-19357000,9714000,6652000,-24619000,-24619000,-52000,-570000,,,,-4265000,6652000,31271000,0,997000,,-19357000,-19357000,330390000.0,115291000.0,15548000.0,22132000.0,130839000.0,1000.0,-330989000.0,35920000.0,16146000.0,8926000.0,56687000.0,47510000.0,1539000.0,,16146000.0,45068000.0,76845000.0,,14676000.0,,5829000.0,3718000.0,596000.0,-1076000.0,55958000.0,-122000.0,-31000.0,389000.0,1213000.0,-409000.0,18165000.0,-1076000.0,-5510000.0,2151000.0,1222000.0,-654000.0,29335000.0,en-US,US,EQUITY,True,Delayed Quote,0.5497645,34.425 - 35.38,0.0,0.0,34.56,30,29,finmb_133103539,NasdaqGS,Immunocore Holdings plc,GBP,70060,133485,6.9799995,0.25135034,27.77 - 61.99,-27.240002,-0.43942574,27.77,61.99,1620802800,1620802800,1620802800,USD,PRE,34.75,1630526402,0.18999863,34.94,35.38,34.425,17471,us_market,2,0,-0.08919105,Immunocore Holdings plc,NMS,-4.73,-7.346723,32.258858,2.4911423,0.07722351,38.152897,-3.402897,1521566976,15,America/New_York,EDT,-14400000,False,False,,,,61.99,27.77,32.26,38.15,70.06k,133.49k,43.79M,,21.57M,0.00%,34.77%,186.17k,4.21,,0.43%,159.33k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-280.43%,-323.25%,-22.77%,-64.85%,30.13M,1.01,0.20%,30.11M,-90.97M,-84.49M,,,313.08M,8.14,63.78M,25.95,6.23,,-56.03M,-27.12M,Value,OX14 4RY,Healthcare,291,"Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung, gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising breast, endometrial, ovarian, and small cell lung cancers; and GSK01 that is in a Phase I clinical trial. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.",Abingdon,44 1235 438600,United Kingdom,http://www.immunocore.com,86400,92 Park Drive,Biotechnology,Milton Park
t-3,IMCR,14771000.0,43786100,20779000,,-21803000,,-18639000,9605000,8255000,-22119000,-22119000,-10000,-1067000,,,,-3164000,8255000,30374000,0,226500,,-18639000,-18639000,330390000.0,120490000.0,14771000.0,22132000.0,153590000.0,1000.0,-311632000.0,41417000.0,14341000.0,9191000.0,56809000.0,43771000.0,1608000.0,,14341000.0,50289000.0,94110000.0,,30798000.0,,4394000.0,-4971000.0,-1334000.0,26149000.0,13666500.0,-5589000.0,114000.0,-30518000.0,-1334000.0,26149000.0,-11879000.0,-1110500.0,-6580000.0,2250500.0,-917000.0,-1036500.0,50339000.0,en-US,US,EQUITY,True,Delayed Quote,0.5497645,34.425 - 35.38,0.0,0.0,34.56,30,29,finmb_133103539,NasdaqGS,Immunocore Holdings plc,GBP,70060,133485,6.9799995,0.25135034,27.77 - 61.99,-27.240002,-0.43942574,27.77,61.99,1620802800,1620802800,1620802800,USD,PRE,34.75,1630526402,0.18999863,34.94,35.38,34.425,17471,us_market,2,0,-0.08919105,Immunocore Holdings plc,NMS,-4.73,-7.346723,32.258858,2.4911423,0.07722351,38.152897,-3.402897,1521566976,15,America/New_York,EDT,-14400000,False,False,,,,61.99,27.77,32.26,38.15,70.06k,133.49k,43.79M,,21.57M,0.00%,34.77%,186.17k,4.21,,0.43%,159.33k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-280.43%,-323.25%,-22.77%,-64.85%,30.13M,1.01,0.20%,30.11M,-90.97M,-84.49M,,,313.08M,8.14,63.78M,25.95,6.23,,-56.03M,-27.12M,Value,OX14 4RY,Healthcare,291,"Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung, gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising breast, endometrial, ovarian, and small cell lung cancers; and GSK01 that is in a Phase I clinical trial. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.",Abingdon,44 1235 438600,United Kingdom,http://www.immunocore.com,86400,92 Park Drive,Biotechnology,Milton Park
